Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

Edor Kabashi wins the International Medicine PG Award for Amyotrophic Lateral Sclerosis (ALS) research

Published on: 26/10/2016 Reading time: 1 min
Edor Kabashi
Retour à la recherche

The Paulo Gontijo Institute awarded the International Medicine PG Award to Edor Kabashi, team leader at the Brain and Spine Institute – Institut du Cerveau, for his research on the development of new models and new therapeutic avenues for Amyotrophic Lateral Sclerosis (ALS).

Edor Kabashi joined the Brain and Spine Institute - Institut du Cerveau - ICM in 2011 as the “Treatment of Amyotrophic lateral sclerosis: from genetics to zebrafish” team leader. He obtained his PhD in 2008 at McGill University and did postdoctoral work at Centre of Excellence in Neuromics at University of Montreal. He received many awards, including the Brain Star Award of CIHR Institute of Neuroscience in 2009 and 2011, and the Young investigator award from European Network for the Cure of ALS in 2015.

The International Medicine PG Award is an initiative of the Paulo Gontijo Institute to foster the research of young researchers around the world to promote the cure of ALS.

Selected from 15 studies, Kabashi’s studies have provided a breakthrough in developing new models and therapeutic avenues for Amyotrophic Lateral Sclerosis (ALS).

 

“My team works to better understand how a variety of genetic mutations can cause motor neuron degeneration in ALS. We take advantage of a simple vertebrate model, zebrafish where one or several genes can be manipulated. Using this paradigm, we have described that several major ALS genes interact together and function in common pathways and we are currently identifying drugs which could affect these molecular targets”, says Edor Kabashi.

 

The International Medicine PG Award is recognized by the international scientific community. Its partners the International Alliance of ALS, Motor Neuron Disease Association (MNDA) and the European Community for research for the cure of ALS (ENCALS). The study results will be presented at opening ceremony of the 26th International Symposium on ALS / MND (motor neuron disease) to be held in Dublin (Ireland) in December.

Our news on the subject

Sclérose en plaques : identification d’une nouvelle molécule favorisant la remyélinisation
Multiple Sclerosis: Identification of a Molecule that Promotes Repair of the Nervous System
A molecule previously studied in the context of sleep disorders and attention deficit hyperactivity disorder (ADHD) is now, for the first time, revealing its potential in experimental models of multiple sclerosis (MS): it protects neurons and...
01.27.2026 Research, science & health
VignetteActu WBHF 2026
World Brain Health Forum 2026
More than one in three people will experience a brain disorder at some point in their lives. This reality, identified by the World Health Organization as a major public health priority, calls for unprecedented international mobilization. It is...
01.12.2026 Events
Une nouvelle approche pour évaluer les patients en état de conscience altérée
A New Approach to Assessing Patients with Disorders of Consciousness
In intensive care units, some patients who appear unconscious occupy a gray zone in their relationship to the world. To better diagnose them and predict their recovery potential, Dragana Manasova, Jacobo Sitt, and their colleagues have developed an...
01.08.2026 Research, science & health
Ne plus penser à rien : vers une signature cérébrale du blanc mental
Not Thinking About Anything: Toward a Brain Signature of Mind Blanking
What if the flow of our thoughts occasionally just stopped? Esteban Munoz-Musat, Lionel Naccache, Thomas Andrillon, and their colleagues at Paris Brain Institute and Monash University in Melbourne show that the sensation of “thinking about nothing”...
12.26.2025 Research, science & health
Deux nouvelles certifications pour les plateformes de l’Institut du Cerveau
Two new certifications for Paris Brain Institute’s core facilities
Paris Brain Institute’s core facilities were recently awarded two new certifications: ISO 9001 certification for ICM.Quant and ISO 20387 certification for its DNA & Cell Bank.
11.14.2025 Institutional
La dépression résistante possède une signature moléculaire spécifique
Treatment-resistant depression identified as a distinct molecular subtype
An international study published in Brain, Behavior, and Immunity shows that patients with treatment-resistant depression (TRD) have a unique biology, different from those who respond to standard therapies. More than 5,000 genes were found to behave...
11.03.2025 Research, science & health
See all our news